Published in:
01-12-2011 | Oral presentation
Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
Authors:
J Baselga, F Costa, H Gomez, C Hudis, B Rapoport, H Roche, LS Schwartzberg, O Petrenciuc, M Shan, WJ Gradishar
Published in:
Breast Cancer Research
|
Special Issue 2/2011
Login to get access
Excerpt
A double-blind, randomized, phase 2b screening trial (SOLTI-0701) of sorafenib, an oral multikinase inhibitor, in patients with HER2-negative advanced breast cancer (BC), showed a statistically significant improvement in progression-free survival (PFS) in the sorafenib + capecitabine arm versus the placebo + capecitabine arm: 6.4 versus 4.1 months (hazard ratio = 0.58; one-sided P = 0.0006). Grade 3/4 toxicities were comparable except G3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% vs. 14%). These results support a phase 3 trial of sorafenib + capecitabine in advanced BC. …